Literature DB >> 27511444

Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma.

S Y Liu1, C M Chu2, A P Kong3, S K Wong1, P W Chiu1, F C Chow3, E K Ng4.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is an emerging treatment for primary aldosteronism owing to aldosterone-producing adenoma. Whether RFA could be an alternative treatment to laparoscopic adrenalectomy is unknown.
METHODS: This was a retrospective comparative study in patients with aldosterone-producing adenoma undergoing either laparoscopic adrenalectomy or CT-guided percutaneous RFA between 2004 and 2012. Short-term outcomes and long-term resolution rates of primary aldosteronism (normalized aldosterone to renin ratio), hypokalaemia and hypertension (BP lower than 140/90 mmHg without antihypertensive medical therapy) were evaluated.
RESULTS: Some 63 patients were included, 27 in the laparoscopic adrenalectomy group and 36 in the RFA group. RFA was associated with shorter duration of operation (median 12 versus 124 min; P < 0·001), shorter hospital stay (2 versus 4 days; P < 0·001), lower analgesic requirements (13 of 36 versus 23 of 27 patients; P < 0·001) and earlier resumption of work (median 4 versus 14 days; P = 0·006). Morbidity rates were similar in the two groups. With median follow-up of 5·7 (range 1·9-10·6) years, resolution of primary aldosteronism was seen in 33 of 36 patients treated with RFA and all 27 patients who had laparoscopic adrenalectomy (P = 0·180). Hypertension was resolved less frequently after treatment with RFA compared with laparoscopic adrenalectomy (13 of 36 versus 19 of 27 patients; P = 0·007). Hypokalaemia was resolved in all patients.
CONCLUSION: For patients with aldosterone-producing adenoma the efficacy of resolution of primary aldosteronism and hypertension was inferior after treatment with RFA compared with laparoscopic adrenalectomy.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27511444     DOI: 10.1002/bjs.10219

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Comparison of the radiofrequency ablation versus laparoscopic adrenalectomy for aldosterone-producing adenoma: a meta-analysis of perioperative outcomes and safety.

Authors:  Run-Qi Guo; Yuan-Ming Li; Xiao-Guang Li
Journal:  Updates Surg       Date:  2021-06-24

Review 2.  Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.

Authors:  Heather Wachtel; Douglas L Fraker
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 3.955

3.  Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Authors:  Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-11       Impact factor: 32.069

4.  Immediate Results and Long-Term Outcomes Following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma.

Authors:  Chien-Hsien Lo; Yeu-Sheng Tyan; Kwo-Chang Ueng
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

Review 5.  Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation.

Authors:  Byung Kwan Park; Masashi Fujimori; Shu-Huei Shen; Uei Pua
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01

6.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.